Early life treatment with vancomycin reduces diabetes incidence in NOD mice

Research output: Contribution to conference › Poster › Research

Standard

Early life treatment with vancomycin reduces diabetes incidence in NOD mice. / Hansen, Camilla Hartmann Friis.

2011. Poster session presented at International Congress of Mucosal Immunology, Paris, France.

Research output: Contribution to conference › Poster › Research

Harvard

Hansen, CHF 2011, 'Early life treatment with vancomycin reduces diabetes incidence in NOD mice', International Congress of Mucosal Immunology, Paris, France, 05/07/2011 - 09/07/2011.

APA

Hansen, C. H. F. (2011). Early life treatment with vancomycin reduces diabetes incidence in NOD mice. Poster session presented at International Congress of Mucosal Immunology, Paris, France.

Vancouver

Hansen CHF. Early life treatment with vancomycin reduces diabetes incidence in NOD mice. 2011. Poster session presented at International Congress of Mucosal Immunology, Paris, France.

Author

Hansen, Camilla Hartmann Friis. / Early life treatment with vancomycin reduces diabetes incidence in NOD mice. Poster session presented at International Congress of Mucosal Immunology, Paris, France.

Bibtex

@conference{ac77eff28fa34a6bb57ae7b44cd2f2a2,
title = "Early life treatment with vancomycin reduces diabetes incidence in NOD mice",
abstract = "Type 1 diabetes (T1D) results from an uncontrolled T cell mediated destruction of the insulin-producing beta-cells in the pancreas. Causal factors include a combination of genetics, early life incidents and the food we eat. The involved adaptive immune response can be down regulated by a regulatory immune response and a fine-tuned balance between these immunological components is crucial for characteristics of the disease, such as severity, onset time and recovery. The balance between the regulatory and the adaptive immune response is heavily influenced by early life bacterial stimulation. An interplay that is likely to represent a critical environmental component to diabetes induction. In a period after birth alterations of the early microbial colonization of the gut therefore can be expected to have an immense impact on diabetes progression later in life. In this study neonate NOD mice were treated with the antibiotic vancomycin in four weeks from birth. Diabetes incidence and onset time were compared with a control group and we found that neonate vancomycin treatment attenuates T1D. By changing the gut flora composition in the beginning of life we also demonstrated a disruption of the mechanisms regulating intestinal immune homeostasis toward a proinflammatory mucosal environment. ",
author = "Hansen, {Camilla Hartmann Friis}",
year = "2011",
month = jun,
language = "English",
note = "null ; Conference date: 05-07-2011 Through 09-07-2011",

}

RIS

TY - CONF

T1 - Early life treatment with vancomycin reduces diabetes incidence in NOD mice

AU - Hansen, Camilla Hartmann Friis

N1 - Conference code: 11

PY - 2011/6

Y1 - 2011/6

N2 - Type 1 diabetes (T1D) results from an uncontrolled T cell mediated destruction of the insulin-producing beta-cells in the pancreas. Causal factors include a combination of genetics, early life incidents and the food we eat. The involved adaptive immune response can be down regulated by a regulatory immune response and a fine-tuned balance between these immunological components is crucial for characteristics of the disease, such as severity, onset time and recovery. The balance between the regulatory and the adaptive immune response is heavily influenced by early life bacterial stimulation. An interplay that is likely to represent a critical environmental component to diabetes induction. In a period after birth alterations of the early microbial colonization of the gut therefore can be expected to have an immense impact on diabetes progression later in life. In this study neonate NOD mice were treated with the antibiotic vancomycin in four weeks from birth. Diabetes incidence and onset time were compared with a control group and we found that neonate vancomycin treatment attenuates T1D. By changing the gut flora composition in the beginning of life we also demonstrated a disruption of the mechanisms regulating intestinal immune homeostasis toward a proinflammatory mucosal environment.

AB - Type 1 diabetes (T1D) results from an uncontrolled T cell mediated destruction of the insulin-producing beta-cells in the pancreas. Causal factors include a combination of genetics, early life incidents and the food we eat. The involved adaptive immune response can be down regulated by a regulatory immune response and a fine-tuned balance between these immunological components is crucial for characteristics of the disease, such as severity, onset time and recovery. The balance between the regulatory and the adaptive immune response is heavily influenced by early life bacterial stimulation. An interplay that is likely to represent a critical environmental component to diabetes induction. In a period after birth alterations of the early microbial colonization of the gut therefore can be expected to have an immense impact on diabetes progression later in life. In this study neonate NOD mice were treated with the antibiotic vancomycin in four weeks from birth. Diabetes incidence and onset time were compared with a control group and we found that neonate vancomycin treatment attenuates T1D. By changing the gut flora composition in the beginning of life we also demonstrated a disruption of the mechanisms regulating intestinal immune homeostasis toward a proinflammatory mucosal environment.

M3 - Poster

Y2 - 5 July 2011 through 9 July 2011

ER -

ID: 37812591